Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863643 | 0.91 | ESR1 (0.49) | ESR1ESR2LTA4H | |
| SCHEMBL5863824 | 0.89 | LTA4H (0.47) | ESR1ESR2HRH3LTA4HPTGS2 | |
| SCHEMBL5864087 | 0.89 | ESR1 (0.45) | ESR1ESR2HRH3LTA4HABCC1 | |
| SCHEMBL5863977 | 0.89 | ESR1 (0.44) | ESR1ESR2HRH3LTA4HPTGS2 | |
| SCHEMBL5863908 | 0.87 | ESR1 (0.48) | ESR1ESR2HRH3LTA4HABCC1 | |
| SCHEMBL5863563 | 0.87 | LTA4H (0.48) | ESR1ESR2HRH3LTA4HPTGS2 | |
| SCHEMBL5864192 | 0.86 | ESR1 (0.42) | ESR1ESR2LTA4HPTGS2ABCC1 | |
| SCHEMBL5863997 | 0.86 | MMP1 (0.44) | ESR1ESR2LTA4HPTGS2ABCC1 | |
| SCHEMBL5863730 | 0.86 | ESR1 (0.50) | ESR1ESR2LTA4HKDM4EPOLB | |
| SCHEMBL5863788 | 0.85 | ESR1 (0.44) | ESR1ESR2ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | claimed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | claimed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | claimed |
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | ESR1 4/4885ESR2 12/4885HRH3 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.